
## Kyong-Mi Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/866892/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67, 1560-1599.	3.6	2,620
2	AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63, 261-283.	3.6	1,662
3	Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection. Journal of Experimental Medicine, 2001, 194, 1395-1406.	4.2	1,091
4	Innate Lymphoid Cells Promote Anatomical Containment of Lymphoid-Resident Commensal Bacteria. Science, 2012, 336, 1321-1325.	6.0	638
5	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature Genetics, 2018, 50, 1514-1523.	9.4	497
6	Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nature Genetics, 2020, 52, 680-691.	9.4	445
7	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	13.7	353
8	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	3.7	342
9	Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade. PLoS Pathogens, 2009, 5, e1000313.	2.1	322
10	Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology, 2001, 33, 267-276.	3.6	316
11	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	3.6	269
12	Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization. Gastroenterology, 2008, 134, 1927-1937.e2.	0.6	263
13	Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8ÂT Cells. Immunity, 2018, 48, 1029-1045.e5.	6.6	250
14	Different affinity windows for virus and cancerâ€specific <scp>T</scp> â€eell receptors: Implications for therapeutic strategies. European Journal of Immunology, 2012, 42, 3174-3179.	1.6	212
15	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology, 2020, 72, 539-557.	1.8	208
16	A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. PLoS ONE, 2013, 8, e63818.	1.1	204
17	Suppression of HCV-specific T cells without differential hierarchy demonstrated in persistent HCV infection. Hepatology, 2003, 38, 1437-1448.	3.6	199
18	Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology, 2016. 150. 684-695.e5.	0.6	178

#	Article	IF	CITATIONS
19	Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nature Medicine, 2019, 25, 1274-1279.	15.2	177
20	Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. American Journal of Human Genetics, 2019, 105, 763-772.	2.6	169
21	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nature Genetics, 2019, 51, 1574-1579.	9.4	152
22	Multiplexed In Situ Imaging Mass Cytometry Analysis of the Human Endocrine Pancreas and Immune System in Type 1 Diabetes. Cell Metabolism, 2019, 29, 769-783.e4.	7.2	151
23	Identification and In Vitro Expansion of Functional Antigen-Specific CD25 <sup>+</sup> FoxP3 <sup>+</sup> Regulatory T Cells in Hepatitis C Virus Infection. Journal of Virology, 2008, 82, 5043-5053.	1.5	150
24	Discordant Role of CD4 T-Cell Response Relative to Neutralizing Antibody and CD8 T-Cell Responses in Acute Hepatitis C. Gastroenterology, 2007, 132, 654-666.	0.6	146
25	American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology, 2021, 74, 1049-1064.	3.6	136
26	Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing. Journal of Virology, 2010, 84, 6218-6228.	1.5	135
27	Hepatitis C virus: virology and life cycle. Clinical and Molecular Hepatology, 2013, 19, 17.	4.5	134
28	Single-Cell Mass Cytometry Analysis of the Human Endocrine Pancreas. Cell Metabolism, 2016, 24, 616-626.	7.2	126
29	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nature Medicine, 2021, 27, 668-676.	15.2	120
30	Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology, 2003, 37, 590-599.	3.6	102
31	A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genetics, 2020, 16, e1008629.	1.5	101
32	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clinical Gastroenterology and Hepatology, 2015, 13, 183-192.	2.4	90
33	Immunopathogenesis of hepatitis C virus infection. Clinics in Liver Disease, 2003, 7, 89-105.	1.0	84
34	Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-Positive B-cell population. Hepatology, 2012, 55, 709-719.	3.6	83
35	Previously Infected Chimpanzees Are Not Consistently Protected against Reinfection or Persistent Infection after Reexposure to the Identical Hepatitis C Virus Strain. Journal of Virology, 2008, 82, 8183-8195.	1.5	81
36	Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program. Circulation, 2020, 142, 1633-1646.	1.6	78

#	Article	IF	CITATIONS
37	Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology, 2004, 40, 892-899.	3.6	72
38	Immunopathology of hepatitis C. Seminars in Immunopathology, 1997, 19, 57-68.	4.0	70
39	Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. Journal of Hepatology, 2008, 48, 903-913.	1.8	70
40	A research agenda for curing chronic hepatitis B virus infection. Hepatology, 2018, 67, 1127-1131.	3.6	70
41	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics, 2022, 54, 761-771.	9.4	68
42	Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns. Journal of Immunological Methods, 2018, 453, 3-10.	0.6	64
43	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. The Lancet Gastroenterology and Hepatology, 2020, 5, 406-417.	3.7	64
44	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. PLoS Medicine, 2020, 17, e1003302.	3.9	63
45	T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology, 2005, 41, 1365-1375.	3.6	53
46	Rare Birds in North America: Acute Hepatitis C Cohorts. Gastroenterology, 2009, 136, 26-31.	0.6	53
47	Human leukocyte antigen class II associations with hepatitis C virus clearance and virusâ€specific CD4 T cell response among Caucasians and African Americans. Hepatology, 2008, 48, 70-79.	3.6	52
48	Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. Nature Communications, 2021, 12, 2579.	5.8	51
49	Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. Circulation, 2021, 144, 353-364.	1.6	47
50	Strain-Specific T-Cell Suppression and Protective Immunity in Patients with Chronic Hepatitis C Virus Infection. Journal of Virology, 2005, 79, 6976-6983.	1.5	43
51	Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers. Clinical Cancer Research, 2009, 15, 4277-4287.	3.2	43
52	Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases. JAMA Network Open, 2021, 4, e2034461.	2.8	42
53	Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 2010, 59, 599-607.	2.0	35
54	Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology, 2004, 40, 892-899.	3.6	35

#	Article	IF	CITATIONS
55	Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. International Journal of Epidemiology, 2020, 49, 1022-1031.	0.9	34
56	Association of <i>APOL1</i> Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program. Circulation, 2019, 140, 1031-1040.	1.6	31
57	<i>APOL1</i> Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. JAMA Internal Medicine, 2022, 182, 386.	2.6	31
58	Degenerate Immunogenicity of an HLA-A2-Restricted Hepatitis B Virus Nucleocapsid Cytotoxic T-Lymphocyte Epitope That Is Also Presented by HLA-B51. Journal of Virology, 2001, 75, 3984-3987.	1.5	30
59	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2541-2551.e2.	2.4	28
60	Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Human Immunology, 1998, 59, 776-782.	1.2	27
61	Regulatory T cells and the liver: A new piece of the puzzle. Hepatology, 2005, 41, 700-702.	3.6	26
62	Prospects for the Global Elimination of Hepatitis B. Annual Review of Virology, 2021, 8, 437-458.	3.0	26
63	Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Current Opinion in Pharmacology, 2016, 30, 93-105.	1.7	25
64	Association Between Genetic Variation in Blood Pressure and Increased Lifetime Risk of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2027-2034.	1.1	24
65	Distinct Features in Natural History and Outcomes of Acute Hepatitis C. Journal of Clinical Gastroenterology, 2015, 49, e31-e40.	1.1	23
66	Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B. PLoS Pathogens, 2019, 15, e1007715.	2.1	23
67	Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology, 2021, 73, 27-37.	3.6	23
68	Racial Difference in Mortality Among U.S. Veterans with HCV/HIV Coinfection. American Journal of Gastroenterology, 2006, 101, 760-767.	0.2	21
69	Regulatory T cells in hepatitis C virus infection. Hepatology Research, 2007, 37, S327-S330.	1.8	17
70	Minority-centric meta-analyses of blood lipid levels identify novel loci in the Population Architecture using Genomics and Epidemiology (PAGE) study. PLoS Genetics, 2020, 16, e1008684.	1.5	17
71	Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. Clinics in Liver Disease, 2016, 20, 629-644.	1.0	16
72	A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program. PLoS Genetics, 2022, 18, e1010113.	1.5	16

#	Article	IF	CITATIONS
73	Hepatitis B Immunology for Clinicians. Clinics in Liver Disease, 2010, 14, 409-424.	1.0	15
74	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. PLoS ONE, 2020, 15, e0237430.	1.1	15
75	Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. JCI Insight, 2021, 6, .	2.3	15
76	Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry. Scientific Reports, 2021, 11, 11645.	1.6	15
77	Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. JAMA Internal Medicine, 0, , .	2.6	15
78	Induction of Multiple Immune Regulatory Pathways with Differential Impact in HCV/HIV Coinfection. Frontiers in Immunology, 2014, 5, 265.	2.2	14
79	Genetic Evidence for Repurposing of GLP1R (Glucagonâ€Like Peptideâ€1 Receptor) Agonists to Prevent Heart Failure. Journal of the American Heart Association, 2021, 10, e020331.	1.6	13
80	IMMUNOPATHOGENESIS OF HEPATITIS B VIRUS INFECTION. Clinics in Liver Disease, 1999, 3, 221-239.	1.0	12
81	Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C monoinfection, and HIV monoinfection. BMC Musculoskeletal Disorders, 2015, 16, 93.	0.8	12
82	A multi-population phenome-wide association study of genetically-predicted height in the Million Veteran Program. PLoS Genetics, 2022, 18, e1010193.	1.5	12
83	Determinants of in vitro expansion of different human virus-specific FoxP3+ regulatory CD8+ T cells in chronic hepatitis C virus infection. Journal of General Virology, 2009, 90, 1692-1701.	1.3	11
84	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. Hepatology, 2021, 73, 1637-1651.	3.6	11
85	A Missense Variant in the IL-6 Receptor and Protection From Peripheral Artery Disease. Circulation Research, 2021, 129, 968-970.	2.0	11
86	Veterans Affairs Office of Research and Development: Research Programs and Emerging Opportunities in Digestive Diseases Research. Gastroenterology, 2015, 149, 1652-1661.	0.6	10
87	PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort. PLoS ONE, 2020, 15, e0239752.	1.1	9
88	Predicting short-term interruptions of antiretroviral therapy from summary adherence data: Development and test of a probability model. PLoS ONE, 2018, 13, e0194713.	1.1	6
89	Genetic determinants of increased body mass index mediate the effect of smoking on increased risk for type 2 diabetes but not coronary artery disease. Human Molecular Genetics, 2020, 29, 3327-3337.	1.4	6
90	Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003501.	1.6	6

#	Article	IF	CITATIONS
91	Long-term use of hydrocodone vs. oxycodone in primary care. Drug and Alcohol Dependence, 2019, 205, 107524.	1.6	5
92	Acute hepatitis C: To treat or not to treat?. Hepatology, 2002, 35, 1538-1540.	3.6	4
93	Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. Journal of Virology, 2017, 91, .	1.5	4
94	Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Digestive Diseases and Sciences, 2016, 61, 1744-1756.	1.1	3
95	Multi-Trait Genome-Wide Association Study of Atherosclerosis Detects Novel Pleiotropic Loci. Frontiers in Genetics, 2021, 12, 787545.	1.1	3
96	Reply. Hepatology, 2018, 68, 1658-1660.	3.6	2
97	Genome-wide and phenome-wide analysis of ideal cardiovascular health in the VA Million Veteran Program. PLoS ONE, 2022, 17, e0267900.	1.1	2
98	Immune Pathogenesis of Viral Hepatitis B and C. , 2012, , 111-128.		1
99	Current status of vaccine therapy for hepatitis c infection. Current Hepatitis Reports, 2006, 5, 68-74.	0.3	0
100	Hepatitis B and the Immune System. Current Hepatitis Reports, 2010, 9, 205-213.	0.3	0
101	Hepatocellular Cancer Induced byÂlnfection. Current Cancer Research, 2019, , 247-259.	0.2	Ο
102	259 Proton pump inhibitor use is not significantly associated with severe COVID-19 related outcomes after extensive covariate adjustment. Journal of Clinical and Translational Science, 2022, 6, 43-43.	0.3	0
103	Title is missing!. , 2020, 16, e1008684.		0
104	Title is missing!. , 2020, 16, e1008684.		0
105	Title is missing!. , 2020, 16, e1008684.		0
106	Title is missing!. , 2020, 16, e1008684.		0
107	Title is missing!. , 2020, 16, e1008684.		0
108	Title is missing! 2020. 16. e1008684.		0

0

#	ARTICLE	IF	CITATIONS
109	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
110	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
111	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
112	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
113	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		Ο
114	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
115	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		О